Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders

British Journal of Pharmacology

Volumn 174, Issue 11, 2017, Pages 1426-1449

  Currò, Diego ^a   Ianiro, Gianluca ^a   Pecere, Silvia ^a   Bibbò, Stefano ^b   Cammarota, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; IBEROGAST; ISPAGULA; MESALAZINE; METHYLCELLULOSE; PEPPERMINT OIL; PLANT MEDICINAL PRODUCT; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

BRAN; CONSTIPATION; DIETARY FIBER; DRUG EFFECT; ESCHERICHIA COLI; HERBAL MEDICINE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE FUNCTION DISORDER; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PLANTAGO OVATA; PRIORITY JOURNAL; REMISSION; REVIEW; SACCHAROMYCES BOULARDII; TREATMENT PLANNING; ULCERATIVE COLITIS; ADMINISTRATION AND DOSAGE; ANIMAL; DIET THERAPY; DIETARY SUPPLEMENT; IRRITABLE COLON; PHYTOTHERAPY; PROCEDURES; QUALITY OF LIFE;

ANIMALS; CONSTIPATION; DIETARY FIBER; DIETARY SUPPLEMENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PHYTOTHERAPY; PLANT PREPARATIONS; PREBIOTICS; PROBIOTICS; QUALITY OF LIFE;

EID: 84995768476     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13632     Document Type: Review

References (222)

1. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M (2011). Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 50: 349–369.
2. Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L et al. (2006). Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55: 1090–1094.
3. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. Br J Pharmacol 172: 5942–5955.
4. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors. Br J Pharmacol 172: 5744–5869.
5. Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. Br J Pharmacol 172: 5904–5941.
6. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
7. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015e). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
8. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015f). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
9. Allam S, Krueger D, Demir IE, Ceyhan G, Zeller F, Schemann M (2015). Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine. Phytomedicine 22: 1063–1070.
10. Ammon HP, Kelber O, Okpanyi SN (2006). Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine 13: 67–74.
11. Barboza JL, Talley NJ, Moshiree B (2014). Current and emerging pharmacotherapeutic options for irritable bowel syndrome. Drugs 74: 1849–1870.
12. Baumgart DC, Sandborn WJ (2012). Crohn's disease. Lancet 380: 1590–1605.
13. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E (2002). Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37: 444–449.
14. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL et al. (2011). Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 60: 923–929.
15. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371: 651–659.
16. Bittner AC, Croffut RM, Stranahan MC (2005). Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 27: 755–761.
17. Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, Tornblom H et al. (2015). Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149: 1399–1407.
18. Bolognini D, Tobin AB, Milligan G, Moss CE (2016). The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol 89: 388–398.
19. Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL et al. (2013). Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 11: 982–987.
20. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD et al. (2005). A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11: 833–839.
21. Boyle RJ, Robins-Browne RM, Tang ML (2006). Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 83: 1256–1264.
22. Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004). Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80: 1618–1625.
23. Brierley SM, Hughes PA, Page AJ, Kwan KY, Martin CM, O'Donnell TA et al. (2009). The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology 137: 2084–2095.
24. Brierley SM, Castro J, Harrington AM, Hughes PA, Page AJ, Rychkov GY et al. (2011). TRPA1 contributes to specific mechanically activated currents and sensory neuron mechanical hypersensitivity. J Physiol 589: 3575–3593.
25. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM (2011). Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 106: 329–336.
26. Brown AC, Rampertab SD, Mullin GE (2011). Existing dietary guidelines for Crohn's disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol 5: 411–425.
27. Butterworth AD, Thomas AG, Akobeng AK (2008). Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev (3): CD006634.
28. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, Motilva V et al. (2007). Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7: 333–342.
29. Cammarota G, Ianiro G, Cianci R, Bibbo S, Gasbarrini A, Currò D (2015). The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 149: 191–212.
30. Cammarota G, Pecere S, Ianiro G, Masucci L, Currò D (2016). Principles of DNA-based gut microbiota assessment and therapeutic efficacy of fecal microbiota transplantation in gastrointestinal diseases. Dig Dis 34: 279–285.
31. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L (2007). Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 39: 530–536.
32. Chen C, Lu M, Pan Q, Fichna J, Zheng L, Wang K et al. (2015a). Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One 10: e0145556.
33. Chen C, Tao C, Liu Z, Lu M, Pan Q, Zheng L et al. (2015b). A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res 29: 1822–1827.
34. Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ (2011). Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol 106: 120–129.
35. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D et al. (2007). Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 52: 385–389.
36. Chey WD, Kurlander J, Eswaran S (2015). Irritable bowel syndrome: a clinical review. JAMA 313: 949–958.
37. Christodoulides S, Dimidi E, Fragkos KC, Farmer AD, Whelan K, Scott SM (2016). Systematic review with meta-analysis: effect of fibre supplementation on chronic idiopathic constipation in adults. Aliment Pharmacol Ther. doi: 10.1111/apt.13662. [Epub ahead of print]
38. Cirillo C, Capasso R (2015). Constipation and Botanical Medicines: An Overview. Phytother Res 29: 1488–1493.
39. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA (2016). Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol 5: e73.
40. Cremonini F (2014). Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials. Neurogastroenterol Motil 26: 893–900.
41. De Smet PA (2004). Health risks of herbal remedies: an update. Clin Pharmacol Ther 76: 1–17.
42. Deguchi Y, Andoh A, Inatomi O, Yagi Y, Bamba S, Araki Y et al. (2007). Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. Dig Dis Sci 52: 2993–2998.
43. Dew MJ, Evans BK, Rhodes J (1984). Peppermint oil for the irritable bowel syndrome: a multicentre trial. Bri J Clin Prac 38: 394, 398.
44. Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A et al. (2014). Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br J Clin Pharmacol 79: 578–592.
45. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M (2014). A systematic review of the safety of probiotics. Expert Opin Drug Saf 13: 227–239.
46. Didari T, Mozaffari S, Nikfar S, Abdollahi M (2015). Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 21: 3072–3084.
47. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF et al. (2010). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 4: 28–62.
48. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M et al. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 6: 991–1030.
49. Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K (2014). The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 100: 1075–1084.
50. Doron S, Snydman DR (2015). Risk and safety of probiotics. Clin Infect Dis 60 (Suppl 2): S129–S134.
51. Durchschein F, Petritsch W, Hammer HF (2016). Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol 22: 2179–2194.
52. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M (2008). On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 53: 1278–1284.
53. Enache-Angoulvant A, Hennequin C (2005). Invasive saccharomyces infection: a comprehensive review. Clin Infect Dis 41: 1559–1568.
54. Eswaran S, Muir J, Chey WD (2013). Fiber and functional gastrointestinal disorders. Am J Gastroenterol 108: 718–727.
55. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, Bergonzelli GE et al. (2007). Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 137: 1901–1907.
56. Everitt H, Moss-Morris R, Sibelli A, Tapp L, Coleman N, Yardley L et al. (2013). Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol 13: 68.
57. Ewaschuk JB, Dieleman LA (2006). Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 12: 5941–5950.
58. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A et al. (1999). Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 94: 427–433.
59. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM et al. (2008). Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337: a2313.
60. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR et al. (2014a). American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109 (Suppl 1): S2–S26.
61. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR et al. (2014b). Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109: 1547–1561.
62. Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S et al. (2014). Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res 28: 1275–1283.
63. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S et al. (2009). A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 25: 520–525.
64. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA et al. (2005). Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54: 242–249.
65. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R (2001). Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 39: 11–17.
66. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW (2014). Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 7: 473–487.
67. Gilardi D, Fiorino G, Genua M, Allocca M, Danese S (2014). Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol 8: 835–846.
68. Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J (2014). Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol 48: 21–28.
69. Grundmann O, Yoon SL (2014). Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol 20: 346–362.
70. Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000). Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45: 1462–1464.
71. Hafer A, Kramer S, Duncker S, Kruger M, Manns MP, Bischoff SC (2007). Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol 7: 36.
72. Hallert C, Kaldma M, Petersson BG (1991). Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 26: 747–750.
73. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG (2015). Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64: 93–100.
74. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I et al. (2004). Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 13: 643–647.
75. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A et al. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 1502–1506.
76. Harrington AM, Hughes PA, Martin CM, Yang J, Castro J, Isaacs NJ et al. (2011). A novel role for TRPM8 in visceral afferent function. Pain 152: 1459–1468.
77. Hartmann RM, Fillmann HS, Martins MI, Meurer L, Marroni NP (2014). Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. Phytother Res 28: 1392–1398.
78. Hatziieremia S, Gray AI, Ferro VA, Paul A, Plevin R (2006). The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macrophages. Br J Pharmacol 149: 188–198.
79. Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ (1988). The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 2: 101–118.
80. Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D (2006). Intestinal spasmolytic effects of STW 5 (Iberogast) and its components. Phytomedicine 13: 75–79.
81. Holtmann G, Talley NJ (2015). Herbal medicines for the treatment of functional and inflammatory bowel disorders. Clin Gastroenterol Hepatol 13: 422–432.
82. Holtmeier W, Zeuzem S, Preiss J, Kruis W, Bohm S, Maaser C et al. (2011). Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 17: 573–582.
83. Horvath A, Dziechciarz P, Szajewska H (2011). Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 33: 1302–1310.
84. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P (2009). A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9: 15.
85. Hunter JO, Tuffnell Q, Lee AJ (1999). Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 129: 1451S–1453S.
86. Irvine EJ, Tack J, Crowell MD, Gwee KA, Ke M, Schmulson MJ et al. (2016). Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 150: 1469–1480.
87. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T (2003). Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22: 56–63.
88. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y et al. (2011). Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 84: 128–133.
89. Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM (2016). A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res 30: 691–700.
90. Jia G, Meng MB, Huang ZW, Qing X, Lei W, Yang XN et al. (2010). Treatment of functional constipation with the Yun-chang capsule: a double-blind, randomized, placebo-controlled, dose-escalation trial. J Gastroenterol Hepatol 25: 487–493.
91. Jian YT, Wang JD, Mai GF, Zhang YL, Lai ZS (2004). [Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis]. Di 1 jun yi da xue xue bao 24: 1353–1358.
92. Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, Fang YX (2005). Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11: 1747–1752.
93. Jiang H, Deng CS, Zhang M, Xia J (2006). Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 12: 3848–3853.
94. Jones JM (2014). CODEX-aligned dietary fiber definitions help to bridge the ‘fiber gap’. Nutr J 13: 34.
95. Jonkers D, Penders J, Masclee A, Pierik M (2012). Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 72: 803–823.
96. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F et al. (2014). Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111: 7421–7426.
97. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y et al. (2006). Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague–Dawley rats. Gut 55: 191–196.
98. Kanauchi O, Agata K (1997). Protein, and dietary fiber-rich new foodstuff from brewer's spent grain increased excretion of feces and jejunum mucosal protein content in rats. Biosci Biotechnol Biochem 61: 29–33.
99. Kanauchi O, Nakamura T, Agata K, Mitsuyama K, Iwanaga T (1998). Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats. J Gastroenterol 33: 179–188.
100. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A et al. (2004). Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20: 1133–1141.
101. Khanna R, MacDonald JK, Levesque BG (2014). Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 48: 505–512.
102. Kim SK, Bhatnagar I (2011). Physical, chemical, and biological properties of wonder kelp--Laminaria. Adv Food Nutr Res 64: 85–96.
103. King TS, Elia M, Hunter JO (1998). Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352: 1187–1189.
104. Kline RM, Kline JJ, Di Palma J, Barbero GJ (2001). Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 138: 125–128.
105. Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE et al. (2001). Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16: 88–95.
106. Krishnareddy S, Swaminath A (2014). When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 20: 1139–1146.
107. Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O (2016). Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med 8: 52.
108. Krueger D, Gruber L, Buhner S, Zeller F, Langer R, Seidl S et al. (2009). The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil 21: 1203–e1110.
109. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M (1997). Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853–858.
110. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M et al. (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623.
111. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M et al. (2016). Bowel disorders. Gastroenterology 150: 1393–1407.
112. Langhorst J, Varnhagen I, Schneider SB, Albrecht U, Rueffer A, Stange R et al. (2013). Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 38: 490–500.
113. Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ et al. (2015). Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 9: 86–106.
114. Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A et al. (2004a). Randomized, double-blind, placebo-controlled trial of oral Aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 19: 739–747.
115. Langmead L, Makins RJ, Rampton DS (2004b). Anti-inflammatory effects of Aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther 19: 521–527.
116. Lee YY (2014). What's new in the toolbox for constipation and fecal incontinence? Front Med 1: 5.
117. Lee HG, Kim H, Oh WK, Yu KA, Choe YK, Ahn JS et al. (2004). Tetramethoxy hydroxyflavone p7F downregulates inflammatory mediators via the inhibition of nuclear factor kappaB. Ann N Y Acad Sci 1030: 555–568.
118. Li Q, Yang GY, Liu JP (2013). Syndrome differentiation in chinese herbal medicine for irritable bowel syndrome: a literature review of randomized trials. Evid Based Complement Alternat Med 2013: 232147.
119. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK (1997). Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 32: 765–768.
120. Liu CY, Muller MH, Glatzle J, Weiser D, Kelber O, Enck P et al. (2004). The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 16: 759–764.
121. Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S (2006). Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev (1): CD004116.
122. Liu W, Guo W, Guo L, Gu Y, Cai P, Xie N et al. (2014). Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response. Int Immunopharmacol 20: 337–345.
123. Lüde S, Vecchio S, Sinno-Tellier S, Dopter A, Mustonen H, Vucinic S et al. (2016). Adverse effects of plant food supplements and plants consumed as food: results from the poisons centres-based PlantLIBRA study. Phytother Res 30: 988–996.
124. Madisch A, Holtmann G, Plein K, Hotz J (2004). Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19: 271–279.
125. Magge SS, Wolf JL (2013). Complementary and alternative medicine and mind–body therapies for treatment of irritable bowel syndrome in women. Womens Health (Lond) 9: 557–567.
126. Mallon P, McKay D, Kirk S, Gardiner K (2007). Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (4): CD005573.
127. Mardini HE, Grigorian AY (2014). Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis 20: 1562–1567.
128. Marquez-Flores YK, Villegas I, Cardeno A, Rosillo MA, Alarcon-de-la-Lastra C (2016). Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways. J Nutr Biochem 30: 143–152.
129. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y et al. (2006). Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842–847.
130. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J (2010). Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 10: 13.
131. Mattia A, Merker R (2008). Regulation of probiotic substances as ingredients in foods: premarket approval or “generally recognized as safe” notification. Clin Infect Dis 46: S115–S118.
132. McFarland LV (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202–2222.
133. McFarland LV (2014). Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open 4: e005047.
134. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R (2010). The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 55: 1385–1390.
135. Michael S, Abdel-Aziz H, Weiser D, Muller CE, Kelber O, Nieber K (2012). Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast(R)) in rat small intestinal preparations. Naunyn Schmiedeberg Arch Pharmacol 385: 411–421.
136. Michelsen KS, Wong MH, Ko B, Thomas LS, Dhall D, Targan SR (2013). HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflamm Bow Dis 19: 151–164.
137. Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T et al. (1998). Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther 12: 1225–1230.
138. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ et al. (2010). The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325–332.
139. Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR et al. (2014). The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 109: 1367–1374.
140. Mueller MH, Gong Q, Kelber O, Kasparek MS, Sibaev A, Mansmann U et al. (2009). A novel herbal preparation desensitizes mesenteric afferents to bradykinin in the rat small intestine. Neurogastroenterol Motil 21: 467–476.
141. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM (2013). Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 11: 1276–1280.
142. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK (2011). Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (12): CD007443.
143. Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T et al. (2010). Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16: 1286–1298.
144. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC (2013). Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther 38: 854–863.
145. Olesen M, Gudmand-Hoyer E (2000). Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr 72: 1570–1575.
146. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G et al. (2012). Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 35: 327–334.
147. Omer B, Krebs S, Omer H, Noor TO (2007). Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14: 87–95.
148. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR et al. (2010). Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 25: 1366–1373.
149. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ (2012). Ulcerative colitis. Lancet 380: 1606–1619.
150. Ottillinger B, Storr M, Malfertheiner P, Allescher HD (2013). STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 163: 65–72.
151. Paineau D, Payen F, Panserieu S, Coulombier G, Sobaszek A, Lartigau I et al. (2008). The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr 99: 311–318.
152. Park MY, Kwon HJ, Sung MK (2011). Dietary aloin, aloesin, or aloe-gel exerts anti-inflammatory activity in a rat colitis model. Life Sci 88: 486–492.
153. Pena JA, Rogers AB, Ge Z, Ng V, Li SY, Fox JG et al. (2005). Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun 73: 912–920.
154. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C et al. (2004). Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127: 1474–1487.
155. Posadzki P, Watson LK, Ernst E (2013). Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med (Lond) 13: 7–12.
156. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C (2002). Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51: 405–409.
157. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M et al. (2008). A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 53: 2524–2531.
158. Rahimi R, Abdollahi M (2012). Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 18: 589–600.
159. Rao SS, Yu S, Fedewa A (2015). Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 41: 1256–1270.
160. Rees WD, Evans BK, Rhodes J (1979). Treating irritable bowel syndrome with peppermint oil. Br Med J 2: 835–836.
161. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT (1999). Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635–639.
162. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I et al. (2010). Prebiotic effects: metabolic and health benefits. Br J Nutr 104: S1–63.
163. Rodriguez-Cabezas ME, Galvez J, Lorente MD, Concha A, Camuesco D, Azzouz S et al. (2002). Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr 132: 3263–3271.
164. Rogha M, Esfahani MZ, Zargarzadeh AH (2014). The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 7: 156–163.
165. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F (2006). Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (4): CD004826.
166. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW (2011). Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev (8): CD003460.
167. Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X et al. (2013). Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 108: 90–98.
168. Sanders ME (2016). Probiotics and microbiota composition. BMC Med 14: 82.
169. Saneian H, Pourmoghaddas Z, Roohafza H, Gholamrezaei A (2015). Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 8: 56–65.
170. Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M (2010). Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 16: 1908–1915.
171. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC (2004). Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 4: 5.
172. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG et al. (2010). Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 105: 2235–2243.
173. Scully P, Macsharry J, O'Mahony D, Lyons A, O'Brien F, Murphy S et al. (2013). Bifidobacterium infantis suppression of Peyer's patch MIP-1alpha and MIP-1beta secretion during Salmonella infection correlates with increased local CD4 + CD25+ T cell numbers. Cell Immunol 281: 134–140.
174. Shanahan F (2012). A commentary on the safety of probiotics. Gastroenterol Clin North Am 41: 869–876.
175. Shen J, Zuo ZX, Mao AP (2014). Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: metaanalysis of randomized controlled trials. Inflamm Bowel Dis 20: 21–35.
176. Sibaev A, Yuece B, Kelber O, Weiser D, Schirra J, Goke B et al. (2006). STW 5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. Phytomedicine 13: 80–89.
177. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR (2009). Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29: 508–518.
178. Simmen U, Kelber O, Okpanyi SN, Jaeggi R, Bueter B, Weiser D (2006). Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 13: 51–55.
179. Singla V, Pratap Mouli V, Garg SK, Rai T, Choudhury BN, Verma P et al. (2014). Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – a randomized, placebo-controlled, pilot study. J Crohns Colitis 8: 208–214.
180. Sivaprakasam S, Prasada PD, Singh N (2016). Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol Ther 164: 144–151.
181. Slavin J (2013). Fiber and prebiotics: mechanisms and health benefits. Nutrients 5: 1417–1435.
182. Somani SJ, Modi KP, Majumdar AS, Sadarani BN (2015). Phytochemicals and their potential usefulness in inflammatory bowel disease. Phytother Res 29: 339–350.
183. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P et al. (2009). The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202–1209.
184. Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP et al. (2010). Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 138: 1772–1782.
185. Southan C, Sharman JL, Benson E, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44 (D1): D1054–D1068.
186. Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. (2016). The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. pii: gutjnl-2015-311240. doi: 10.1136/gutjnl-2015-311240. [Epub ahead of print]
187. Spiller R (2016). Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res. 5. pii: F1000 Faculty Rev-780. doi: 10.12688/f1000research.7992.1. eCollection 2016.
188. Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM et al. (2012). Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142: 1510–1518.
189. Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV et al. (2010). Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 32: 872–883.
190. Storr M, Sibaev A, Weiser D, Kelber O, Schirra J, Goke B et al. (2004). Herbal extracts modulate the amplitude and frequency of slow waves in circular smooth muscle of mouse small intestine. Digestion 70: 257–264.
191. Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN (2014). Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis 20: 472–480.
192. Suares NC, Ford AC (2011). Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 106: 1582–1591.
193. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T et al. (2002). Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123: 1912–1922.
194. Szajewska H (2014). Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. Eur J Pediatr 173: 975.
195. Talley NJ, Butterfield JH (1996). Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome. Am J Gastroenterol 91: 1675–1676.
196. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ (2011). Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 33: 194–202.
197. Thomas A, Quigley EM (2015). Diet and irritable bowel syndrome. Curr Opin Gastroenterol 31: 166–171.
198. Tiequn B, Guanqun C, Shuo Z (2015). Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med 54: 243–249.
199. Tomlin J, Read NW (1988). Laxative properties of indigestible plastic particles. BMJ 297: 1175–1176.
200. Toskes PP, Connery KL, Ritchey TW (1993). Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 7: 87–92.
201. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F (2004). Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 5: 169–174.
202. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A et al. (2012). Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 55: 340–361.
203. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A (2004). Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10: PI126–PI131.
204. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM et al. (2010). Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105: 2218–2227.
205. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK (2003). Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139: 209–218.
206. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F et al. (2007). Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 13: 135–142.
207. Vejdani R, Shalmani HR, Mir-Fattahi M, Sajed-Nia F, Abdollahi M, Zali MR et al. (2006). The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study. Dig Dis Sci 51: 1501–1507.
208. Venugopalan V, Shriner KA, Wong-Beringer A (2010). Regulatory oversight and safety of probiotic use. Emerg Infect Dis 16: 1661–1665.
209. Verdu EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W et al. (2006). Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182–190.
210. Wasilewski A, Zielińska M, Storr M, Fichna J (2015). Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm Bowel Dis 21: 1674–1682.
211. Wegener T, Wagner H (2006). The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine 13: 20–35.
212. Whelan K (2011). Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 14: 581–587.
213. Whelan K, Myers CE (2010). Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomised controlled trials, and nonrandomised trials. Am J Clin Nutr 91: 687–703.
214. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ (2011). A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 5: 115–121.
215. Williams NT (2010). Probiotics. Am J Health Syst Pharm 67: 449–458.
216. Xiao HT, Zhong L, Tsang SW, Lin ZS, Bian ZX (2015). Traditional Chinese medicine formulas for irritable bowel syndrome: from ancient wisdoms to scientific understandings. Am J Chin Med 43: 1–23.
217. Ye Y, Pang Z, Chen W, Ju S, Zhou C (2015). The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med 8: 22529–22542.
218. Zallot C, Quilliot D, Chevaux JB, Peyrin-Biroulet C, Gueant-Rodriguez RM, Freling E et al. (2013). Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis 19: 66–72.
219. Zhang M, Deng C, Zheng J, Xia J, Sheng D (2006a). Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol 6: 1233–1242.
220. Zhang M, Deng CS, Zheng JJ, Xia J (2006b). Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 27: 1071–1077.
221. Zigra PI, Maipa VE, Alamanos YP (2007). Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med 65: 411–418.
222. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M et al. (2006). Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23: 1567–1574.